Jason Keith Eustace
First SEC filing: April 29, 2021 · Latest: April 29, 2021
Insider at
Insider transactions
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
No open-market trades on record; showing all filings.
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| May 20, 2022 | CURI | F | 18 | $1.62 | $29 | 39,529 Direct | -0.05% | Disposed | 79.6% (price as of 2026-10-02) |
| April 20, 2022 | CURI | F | 18 | $2.53 | $46 | 41,572 Direct | -0.04% | Disposed | 15.0% (price as of 2026-10-02) |
| Feb. 18, 2022 | CURI | F | 21 | $3.51 | $74 | 46,432 Direct | -0.05% | Disposed | -17.1% (price as of 2026-10-02) |
| Jan. 20, 2022 | CURI | F | 21 | $4.55 | $96 | 46,453 Direct | -0.05% | Disposed | -36.0% (price as of 2026-10-02) |
| Jan. 1, 2022 | CURI | A | 71,847 | · | · | 71,847 Direct | · | Acquired | (price as of 2026-10-02) |
| Jan. 1, 2022 | CURI | A | 17,706 | · | · | 17,706 Direct | · | Acquired | (price as of 2026-10-02) |
| Dec. 23, 2021 | CURI | F | 43 | $6.44 | $277 | 46,474 Direct | -0.09% | Disposed | -54.8% (price as of 2026-10-02) |
| Dec. 20, 2021 | CURI | F | 18 | $5.70 | $103 | 46,517 Direct | -0.04% | Disposed | -48.9% (price as of 2026-10-02) |
| Nov. 19, 2021 | CURI | F | 18 | $8.03 | $145 | 39,547 Direct | -0.05% | Disposed | -63.8% (price as of 2026-10-02) |
| Nov. 5, 2021 | CURI | F | 2,031 | $9.40 | $19,091 | 39,565 Direct | -4.88% | Disposed | -69.0% (price as of 2026-10-02) |
| Oct. 20, 2021 | CURI | F | 18 | $10.57 | $190 | 41,596 Direct | -0.04% | Disposed | -72.5% (price as of 2026-10-02) |
| Sept. 24, 2021 | CURI | F | 42 | $11.09 | $466 | 41,614 Direct | -0.10% | Disposed | -73.8% (price as of 2026-10-02) |
| Sept. 20, 2021 | CURI | A | 13,824 | · | · | 13,824 Direct | · | Acquired | (price as of 2026-10-02) |
| Sept. 20, 2021 | CURI | A | 2,576 | · | · | 46,535 Direct | +5.86% | Acquired | (price as of 2026-10-02) |
| July 1, 2021 | CURI | F | 42 | $14.44 | $606 | 46,535 Direct | -0.09% | Disposed | -79.8% (price as of 2026-10-02) |
| April 27, 2021 | CURI | A | 4,758 | · | · | 4,758 Direct | · | Acquired | (price as of 2026-10-02) |
| March 25, 2021 | CURI | A | 6,122 | · | · | 6,122 Direct | · | Acquired | (price as of 2026-10-02) |
| March 25, 2021 | CURI | A | 2,032 | · | · | 39,243 Direct | +5.46% | Acquired | (price as of 2026-10-02) |
| Jan. 4, 2021 | CURI | A | 12,180 | · | · | 37,211 Direct | +48.66% | Acquired | (price as of 2026-10-02) |
| Nov. 5, 2020 | CURI | A | 25,031 | · | · | 25,031 Direct | · | Acquired | (price as of 2026-10-02) |
| Nov. 2, 2020 | CURI | A | 101,571 | · | · | 101,571 Direct | · | Acquired | (price as of 2026-10-02) |
| Oct. 14, 2020 | CURI | A | 94,678 | · | · | 94,678 Direct | · | Acquired | (price as of 2026-10-02) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II) Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| Jan. 1, 2022 | CURI | Stock Options (right to buy) | Common Stock | $5.93 | Jan. 1, 2032 | 71,847 | Acquired |
| Jan. 1, 2022 | CURI | Restricted Stock Units | Common Stock | · | · | 17,706 | Acquired |
| Sept. 20, 2021 | CURI | Stock Option (right to buy) | Common Stock | $11.60 | · | 13,824 | Acquired |
| April 27, 2021 | CURI | Stock Option (right to buy) | Common Stock | $15.00 | April 27, 2031 | 4,758 | Acquired |
| March 25, 2021 | CURI | Stock Option (right to buy) | Common Stock | $14.70 | March 24, 2031 | 6,122 | Acquired |
| Nov. 2, 2020 | CURI | Stock Option (right to buy) | Common Stock | $11.50 | Nov. 2, 2025 | 101,571 | Acquired |
| Oct. 14, 2020 | CURI | Stock Option (right to buy) | Common Stock | $5.88 | Feb. 16, 2030 | 94,678 | Acquired |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2022 | $121,632 | · | $104,997 | $244,998 | · | · | · | $471,627 |
| 2021 | $290,000 | · | $259,748 | $179,944 | $104,400 | · | $11,600 | $845,692 |
| 2020 | $253,750 | $30,000 | $237,071 | $743,986 | $74,313 | · | $6,767 | $1,345,887 |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.